Did Vanda Pharmaceuticals beat or miss consensus estimates last quarter?

What does Vanda Pharmaceuticals do and what are its main business segments?

What is the market's earnings forecast for Vanda Pharmaceuticals next quarter?

What factors drove the changes in Vanda Pharmaceuticals's revenue and profit?

What were the key takeaways from Vanda Pharmaceuticals's earnings call?

What is Vanda Pharmaceuticals's latest dividend and current dividend yield?

What were the key takeaways from Vanda Pharmaceuticals’s earnings call?

What is Vanda Pharmaceuticals's gross profit margin?

- **Fanapt Dominance**: 24% revenue growth (2025) and 36% Q4 TRx growth, driven by new patient starts and direct-to-consumer campaigns.
- **Nereus Breakthrough**: FDA-approved for motion sickness, with Phase III GLP-1 trial set to begin H1 2026. 2026 launch expected late Q2/Q3.
- **Pipeline Momentum**: Vasanti NDA under review, Imsidolimab BLA filed, and Visante Phase III for MDD ongoing.
- **Financial Outlook**: 2026 revenue guidance $230-$260 million (+13% YoY), with Fanapt sales targeting $150-$170 million (+36%-40% YoY).
- **Risks**: HETLIOZ generic erosion (2025 sales -7%), PONVORY growth constrained by market access challenges.

**【CEO Summary Section】**
- **Fanapt Growth**: Full-year net product sales increased 24% to $117.3 million, driven by a 28% rise in total prescriptions and 149% surge in new-to-brand prescriptions. Direct-to-consumer campaigns boosted brand awareness.
- **New Product Wins**: FDA approval of Nereus (tradipitant) for motion sickness prevention, the first new oral option in 40 years. Phase III trial for GLP-1 receptor agonist-induced vomiting expected to begin in H1 2026.
- **Pipeline Expansion**: Vasanti (iloperidone) NDA under review for bipolar 1 disorder and schizophrenia with a PDUFA date of February 21, 2026. Imsidolimab BLA submitted for generalized pustular psoriasis.
- **Revenue Outlook**: 2026 total revenues projected at $230-$260 million, with Fanapt sales expected to grow 36%-40% YoY.

**【CFO Financial Commentary】**
- **Full-Year Results**: Total revenue $216.1 million (9% YoY growth). Fanapt sales $117.3 million (24% YoY), offset by HETLIOZ decline (-7%) due to generics.
- **Q4 Highlights**: Total revenue $57.2 million (8% YoY growth). Fanapt Q4 sales $33.2 million (25% YoY), HETLIOZ $16.4 million (-18% YoY), PONVORY $7.6 million (17% YoY).
- **Financial Health**: Cash balance $263.8 million as of Q4 2025. 2026 cash burn expected to exceed 2025 levels due to commercial and R&D investments.
- **Gross-to-Net Dynamics**: Fanapt gross-to-net ~50%, while Vasanti expected to reset to mid-30% due to new Medicaid URA.

**【Q&A Key Highlights】**
- **Vasanti Launch**: Commercial availability expected late Q2/Q3 2026. No day-one cannibalization of Fanapt; focus on new patient starts.
- **Nereus Pricing**: List price expected to be premium to Dramamine/scopolamine, with potential for rapid adoption in motion sickness and GLP-1 markets.
- **LAI Enrollment**: Phase III iloperidone LAI enrollment slow due to European regulatory challenges; U.S. recruitment accelerating.
- **PONVORY Growth**: 2026 net product sales guidance of $80-$90 million assumes modest growth despite generic competition.


Vanda Pharmaceuticals Inc.(VNDA)-20260212-2025 Q4 Earnings call transcript

- **Revenue Beat**: Q3 2025 net product sales $56.3M (+18% YoY), driven by Fanapt (+31%) and HETLIOZ (+35% new prescriptions). 
- **Pipeline Momentum**: 6 potential 2026 launches including tradipitant (FDA Dec 30), Bysanti (FDA Feb 21), and imsidolimab (BLA Q4). 
- **Commercial Expansion**: 300-rep Fanapt sales force achieved 20%+ call volume growth; PONVORY demand up 20% QoQ. 
- **Financial Focus**: 2025 revenue guidance $210-230M, with $293.8M cash as of Q3. 
- **FDA Collaboration**: Positive interactions on tradipitant and HETLIOZ, with priority review for imsidolimab.

**【CEO Summary Section】**
- **Revenue Growth**: Total net product sales reached $56.3 million for Q3 2025, up 18% YoY, driven by Fanapt (31% growth) and HETLIOZ (35% new prescriptions). 
- **Pipeline Progress**: Multiple regulatory milestones include tradipitant (motion sickness, FDA PDUFA Dec 30, 2025), Bysanti (bipolar/schizophrenia, PDUFA Feb 21, 2026), and imsidolimab (psoriasis, BLA submission Q4 2025). 
- **Commercial Expansion**: Fanapt sales force expanded to 300 reps, achieving 20%+ call volume growth QoQ. Direct-to-consumer campaigns boosted brand awareness for Fanapt and PONVORY.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Net loss of $22.6M vs. $5.3M YoY, driven by $87.5M operating expenses (30% YoY growth). 
- **Revenue Guidance**: 2025 total revenue $210-230M (narrowed from $210-250M), reflecting strong Fanapt growth but variable HETLIOZ sales. 
- **Cash Position**: $293.8M as of Q3, down $80.9M YoY due to net loss and operating cash outflows. 
- **Product Performance**: Fanapt inventory at wholesalers stable at 4 weeks, HETLIOZ retains 70%+ market share despite generics.

**【Q&A Key Highlights】**
- **FDA Interactions**: Positive collaborative framework with FDA; tradipitant motion sickness approval expected Dec 30, 2025. Bysanti label discussions likely Q1 2026. 
- **PONVORY Growth**: 20% QoQ growth in underlying demand, with 50-person specialty sales force now fully deployed. 
- **Pipeline Strategy**: Direct-to-consumer campaigns and starter packs key to transitioning Fanapt patients to Bysanti post-approval. 
- **R&D Investments**: $269.7M in R&D/SG&A for first 9 months, supporting 6 potential 2026 product launches (Fanapt, HETLIOZ, PONVORY, tradipitant, Bysanti, imsidolimab).

Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript

- **Fanapt Growth Accelerates**: Q2 revenue up 27% YoY to $29.3 million, with prescriptions +24% YoY and new patient starts +200% YoY.
- **Sales Force Expansion**: 300 reps now selling Fanapt (vs 100 in Q2 2024), with calls up 40% QoQ and 400% YoY.
- **2025 Guidance**: $210-250 million total revenue target, driven by Fanapt and PONVORY growth offsetting HETLIOZ decline.
- **Bysanti Launch Risk/Reward**: Potential Q3 2026 launch with minimal incremental cost, but dependent on FDA approval.
- **PONVORY Uncertainty**: $3 million of 2024 revenue in dispute; Q2 2025 sales reflect resolved uncertainties but growth constrained by specialty pharmacy inventory.

**【CFO Opening Remarks】**
- Total revenue for Q2 2025 was $52.6 million, a 4% increase YoY, driven by Fanapt's 27% revenue growth to $29.3 million.
- Fanapt prescriptions grew 24% YoY, with new patient starts (NBRx) up over 200% YoY.
- HETLIOZ sales declined 13% YoY to $16.2 million due to generic competition, though it retained majority market share.
- PONVORY sales were $7.1 million, up 26% QoQ but down 18% YoY, with new prescriptions at record highs.
- Net loss for Q2 was $27.2 million, wider than $4.5 million YoY, due to higher SG&A and R&D expenses.

**【CEO Commercial Update】**
- Fanapt sales force expanded to 300 reps (from 100 in Q2 2024), with calls up 40% QoQ and 400% YoY.
- PONVORY sales force growing to 50 reps, with new prescriptions at record levels.
- Direct-to-consumer campaigns for Fanapt and PONVORY continue to build brand awareness.
- 2025 financial guidance: Total revenue $210-250 million, year-end cash $280-320 million.

**【CFO Financial Details】**
- H1 2025 revenue $102.6 million (+5% YoY), with Fanapt up 21% to $52.8 million.
- Operating expenses rose 56% YoY to $182.2 million, driven by commercial launch costs.
- Cash balance $325.6 million as of June 30, down $49.1 million YoY.
- Fanapt gross to net ~50%, while Bysanti (if approved) could have ~25-30% gross to net due to lower Medicaid rebate exposure.

**【Q&A Highlights】**
- **Bysanti Launch**: Target Q3 2026 launch if FDA approves on PDUFA date. Existing Fanapt sales force can be repurposed, requiring minimal incremental investment.
- **PONVORY Dispute**: $3 million of 2024 revenue subject to dispute over gross-to-net adjustments; Q2 2025 sales reflect resolved uncertainties.
- **Tradipitant Motion Sickness**: NDA target action date December 30, 2025. Preclinical and clinical safety data robust; potential launch Q1 2026.
- **Bysanti MDD Study**: Single Phase III study may suffice if data strong, though FDA typically prefers two studies for first-time approvals.
- **Medicaid Impact**: Fanapt has 100% Medicaid rebate, while Bysanti could have ~23.1% statutory rebate at launch.


Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

- **Fanapt Dominance**: Q1 2025 prescriptions up 14% YoY, 2,000 weekly TRxs milestone, fastest-growing atypical antipsychotic.
- **Pipeline Expansion**: 6 potential 2026 commercial products, including motion sickness (Tradipitant), bipolar (Bysanti), and psoriasis (Imsidolimab).
- **Financial Resilience**: $50M Q1 revenue (+5% YoY), guiding to $210-250M 2025 despite $29.5M net loss, supported by $340M cash.
- **Growth Drivers**: Fanapt sales force expansion to 300 reps, PONVORY prescriptions at record high, HETLIOZ market share retention despite generics.
- **Risks**: HETLIOZ volume decline potential, Medicare benefit redesign impacting gross-to-net margins.


**【CEO Key Highlights】**
- **Fanapt Growth**: Q1 2025 prescriptions up 14% YoY, new patient starts tripled, reaching 2,000 weekly TRxs in April 2025, making it one of the fastest-growing atypical antipsychotics.
- **Pipeline Momentum**: 6 potential commercial products by 2026, including Tradipitant (motion sickness), Bysanti (bipolar I disorder), and Imsidolimab (psoriasis).
- **Sales Force Expansion**: Psychiatry sales force expanded to 300 reps, PONVORY sales force to 40 reps, driving prescriber engagement (+43% face-to-face calls in April 2025).

**【CFO Financial Summary】**
- **Total Revenue**: $50 million (Q1 2025), +5% YoY, driven by Fanapt (+14%) and HETLIOZ (+4%).
- **Net Loss**: $29.5 million (Q1 2025) vs. $4.1 million (Q1 2024), due to $15M Anaptys license payment and commercial launch expenses.
- **Cash Position**: $340.9 million as of March 2025, guiding to $280-320 million by year-end 2025.
- **Revenue Guidance**: $210-250 million for 2025, implying 6-26% YoY growth, with Fanapt back-weighted growth offsetting HETLIOZ generic competition.

**【Q&A Key Takeaways】**
- **Bysanti MDD Trial**: Phase III data expected 2026; primary endpoint: change from baseline on HAMD/MADRS vs. placebo, with focus on tolerability (Akathisia, neuropathy).
- **Tradipitant Gastroparesis**: FDA review process ongoing; no refile needed, potential hearing determination pending.
- **Europe Strategy**: Fanapt/Europe MAAs submitted; focus on Germany's reimbursement environment for oral/long-acting antipsychotics.
- **Direct-to-Consumer (DTC)**: Bipolar-focused campaigns launched Q1 2025, with early traction in new patient starts and prescriber engagement.


Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 2024 revenue up 3% to $198.8M, driven by Fanapt (+4%) and PONVORY (+$27.8M). Q4 Fanapt sales +18% YoY, NBRx +160% YoY.
- **Pipeline Momentum**: 
  - **Bysanti**: NDA submission Q1 2025; MDD Phase III underway.
  - **Imsidolimab**: BLA for GPP planned 2025.
  - **Tradipitant**: FDA decision on motion sickness NDA expected 2025.
- **Strategic Moves**: 
  - Expanded sales force to 300 reps; DTC ads launched for Fanapt.
  - Fanapt LAI Phase III for schizophrenia under evaluation.
- **2025 Outlook**: Revenue $210-250M (6-26% growth), excluding unapproved products. Medicare changes may impact margins.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue for 2024 was $198.8 million, up 3% from 2023, driven by Fanapt ($94.3M, +4%) and PONVORY ($27.8M). Fanapt net sales in Q4 2024 increased 18% YoY, with new patient starts (NBRx) up 160% YoY.
- **Pipeline Progress**: 
  - **Bysanti (mlsaperidone)**: NDA submission for bipolar I disorder/schizophrenia expected Q1 2025; Phase III for MDD initiated Q4 2024.
  - **Imsidolimab (IL-36 receptor antagonist)**: BLA submission for generalized pustular psoriasis (GPP) planned for 2025.
  - **Tradipitant**: NDA for motion sickness filed Q4 2024, with FDA decision expected 2025.
- **Strategic Initiatives**: 
  - Expanded sales force to 300 reps for Fanapt; DTC advertising launched in January 2025.
  - Fanapt LAI Phase III for schizophrenia maintenance under evaluation post-IRB concerns; hypertension benefit identified in meta-analysis.

**【CFO Financial Commentary】**
- **2024 Financials**: Net loss of $18.9 million vs. net income $2.5M in 2023. Operating expenses rose 15% to $239.4M due to commercial launches.
- **2025 Guidance**: Total revenue $210-250M (6-26% growth), excluding contributions from unapproved products. Medicare benefit redesign may negatively impact gross-to-net margins.
- **Cash Position**: $374.6M as of Dec 31, 2024, with no 2025 cash guidance due to regulatory filing costs and commercial investments.

**【Q&A Highlights】**
- **Sales Force Expansion**: CEO expects 300 reps sufficient for Fanapt, despite potential competition from larger pharma (e.g., J&J's Caplyta).
- **DTC Effectiveness**: CEO confident DTC ads will increase patient awareness and prescriber confidence, with measured ROI approach.
- **Bysanti Strategy**: Focus on once-daily dosing convenience for MDD, leveraging Fanapt's pharmacokinetics.
- **Competitive Landscape**: CEO notes limited generic competition for HETLIOZ and stable pipeline for 2025-2026 product launches (6 products by 2026).

Actual											0.01	0.16	0.11	0.15	0.15	0.17	0.14	0.12	-0.11	0.05	0.06	0.12	0.06	0.03	0	-0.04	-0.07	-0.08	-0.09	-0.08	-0.5	-0.46	-0.38	-2.39
Forecast											-0.03	0.0553	0.0953	0.1412	0.08	0.15	0.19	0.085	-0.01	0.14	0.1	0.08		-0.13	-0.04	-0.09	0.05	-0.19	-0.1567	-0.1067	-0.5733	-0.3567	-0.4333	-0.975
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+133.33%	+189.33%	+15.42%	+6.23%	+87.50%	+13.33%	-26.32%	+41.18%	-1000.00%	-64.29%	-40.00%	+50.00%	0.00%	+123.08%	+100.00%	+55.56%	-240.00%	+57.89%	+42.57%	+25.02%	+12.79%	-28.96%	+12.30%	-145.13%

Actual	--	--	--	--	--	--	--	--	--	--	58.00M	62.21M	60.31M	67.65M	62.67M	67.90M	70.09M	68.02M	60.19M	64.39M	65.32M	64.48M	62.50M	46.06M	38.81M	45.27M	47.46M	50.47M	47.65M	53.19M	50.04M	52.59M	56.26M	57.22M
Forecast	--	--	--	--	--	--	--	--	--	--	56.87M	61.95M	64.20M	64.00M	64.20M	69.75M	74.25M	70.04M	58.00M	67.00M	71.00M	67.60M	--	49.00M	44.50M	37.00M	48.50M	47.90M	49.17M	52.25M	45.13M	54.77M	58.83M	59.27M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.99%	+0.41%	-6.06%	+5.71%	-2.38%	-2.65%	-5.60%	-2.88%	+3.78%	-3.90%	-8.00%	-4.61%	0.00%	-6.01%	-12.78%	+22.35%	-2.14%	+5.37%	-3.08%	+1.79%	+10.87%	-3.97%	-4.38%	-3.47%

VNDA

VNDA fundamentals

VNDA Q4 2025 Earnings

Earnings Call

You can ask Aime

VNDA

VNDA fundamentals

VNDA Q4 2025 Earnings

Earnings Call

VNDA Earnings Call Summary for Q4/20254:30 PM on Feb 11, 2026

VNDA Earnings Call Summary for Q3/20254:30 PM on Oct 29, 2025

VNDA Earnings Call Summary for Q2/20258:00 AM on Jul 31, 2025

VNDA Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

VNDA Earnings Call Summary for Q4/20244:30 PM on Feb 13, 2025

You can ask Aime